Jan 6, 2021

New remote monitoring device launches for heart diseases

heart monitor
cardiovascular health
remote health monitor
Leila Hawkins
2 min
New remote monitoring device launches for heart diseases
The device is launching to help people monitor heart conditions from home...

Latvian healthtech startup UPOlife is launching a remote health monitoring solution to help tackle cardiovascular diseases in Europe. 

UPOlife's new heart monitoring product is a personal, pocket-size, portable electrocardiogram device that works in combination with an app and cloud-based AI analytics.

The solution allows patients to monitor their own heart health without having to visit a doctor. Users are able to perform a 60 second ECG reading, along with calculating their risk of heart disorders, stamina, emotional, stress, and fatigue scores. 

Over a seven day period, machine learning algorithms create a personal baseline. Results are uploaded to a cloud server via Bluetooth, and AI algorithms analyse the data and provide fast results on the patient’s phone. They can then share their results with their doctors, even if they don't use the UPOlife platform.

Cardiovascular diseases are disorders of the heart and blood vessels including coronary heart disease, and rheumatic heart disease among other conditions. 

According to the World Health Organisation (WHO) they are the top cause of death globally, with an estimated 17.9 million people dying each year. Four out of five cardiovascular deaths are due to heart attacks and strokes, and one third of these deaths occur prematurely in people under 70 years of age.

UPOlife's heart monitoring device has received approval from Latvian clinicians who are taking part in the startup's ongoing pilot project on early screening and diagnostics of arrhythmias. 

The project involves general practitioners and their patients from different cities around Latvia, where cardiovascular diseases are the leading cause of death, accounting for 50-60 per cent of all deaths.

With the new device UPOlife aim to make heart health care more widely available despite the global pandemic, which is limiting access to doctors as patients self-isolate at home. “Our aim is to cooperate with the doctors, giving them access to remote heart health monitoring tools and automatic data analytics, at the same time also allowing patients to subscribe to our solution directly for self-monitoring” says the company's founder Normunds Daudiss. 

Share article

Jun 18, 2021

Skin Analytics wins NHSX award for AI skin cancer tool 

AI
NHS
skincancer
Cancer
2 min
Skin Analytics uses AI to detect skin cancer and will be deployed across the NHS to ease patient backlogs

An artificial intelligence-driven tool that identifies skin cancers has received an award from NHSX, the NHS England and Department of Health and Social Care's initiative to bring technology into the UK's national health system. 

NHSX has granted the Artificial Intelligence in Health and Care Award to DERM, an AI solution that can identify 11 types of skin lesion. 

Developed by Skin Analytics, DERM analyses images of skin lesions using algorithms. Within primary care, Skin Analytics will be used as an additional tool to help doctors with their decision making. 

In secondary care, it enables AI telehealth hubs to support dermatologists with triage, directing patients to the right next step. This will help speed up diagnosis, and patients with benign skin lesions can be identified earlier, redirecting them away from dermatology departments that are at full capacity due to the COVID-19 backlog. 

Cancer Research has called the impact of the pandemic on cancer services "devastating", with a 42% drop in the number of people starting cancer treatment after screening. 

DERM is already in use at University Hospitals Birmingham and Mid and South Essex Health & Care Partnership, where it has led to a significant reduction in unnecessary referrals to hospital.

Now NHSX have granted it the Phase 4 AI in Health and Care Award, making DERM available to clinicians across the country. Overall this award makes £140 million available over four years to accelerate the use of artificial intelligence technologies which meet the aims of the NHS Long Term Plan.

Dr Lucy Thomas, Consultant Dermatologist at Chelsea & Westminster Hospital, said: “Skin Analytics’ receipt of this award is great news for the NHS and dermatology departments. It will allow us to gather real-world data to demonstrate the benefits of AI on patient pathways and workforce challenges. 

"Like many services, dermatology has severe backlogs due to the COVID-19 pandemic. This award couldn't have come at a better time to aid recovery and give us more time with the patients most in need of our help.”

Share article